Weekly Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings

June 27, 2018 - By Ira Colvard

During 2018 Q1 the big money sentiment decreased to 1.19. That’s change of 0.01, from 2017Q4’s 1.2. 18 investors sold all, 46 reduced holdings as Aerie Pharmaceuticals, Inc. ratio worsened. 59 grew stakes while 17 funds acquired stakes. Funds hold 39.43 million shares thus 13.11% more from 2017Q4’s 34.86 million shares.
Foresite Mngmt Ii Ltd Liability accumulated 1.67M shs. Morgan Stanley reported 0.01% stake. Rhumbline Advisers holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 31,792 shs. Glenmede Trust Na accumulated 714 shs. Jgp Gestao De Recursos Ltda stated it has 0.3% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Fmr Limited Liability invested in 0.01% or 874,070 shs. Moreover, Raymond James And Assoc has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Atwood And Palmer invested in 0% or 200 shs. Perigon Wealth Management Lc has invested 0.02% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). C Group Inc Hldg A S stated it has 72,739 shs. Qs Investors Ltd Limited Liability Company stated it has 2,100 shs. Senzar Asset Ltd holds 1.21% or 70,668 shs. Next Century Growth Lc owns 73,979 shs or 0.54% of their US capital. 455,450 are held by Voya Invest Management. Marshall Wace Limited Liability Partnership stated it has 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Aerie Pharmaceuticals, Inc. registered $13.13 million net activity with 2 insider purchases and 4 selling transactions since May 21, 2018. Kopczynski Casey C. sold 2,708 shs worth $135,806. On Wednesday, June 6 $9.34 million worth of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was sold by ANIDO VICENTE JR.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 6 have positions in Aerie Pharma (NASDAQ:AERI) as follows: 6 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 2, 2018 according to StockzIntelligence Inc Aerie Pharma has 10 analyst reports. On Wednesday, May 9 the firm has “Buy” rating given by Mizuho. On Wednesday, January 24 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Canaccord Genuity. In Thursday, March 1 report H.C. Wainwright maintained the stock with “Buy” rating. On Tuesday, May 8 the stock has “Buy” rating by Cantor Fitzgerald. On Wednesday, May 9 H.C. Wainwright maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. In Wednesday, February 28 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Friday, February 16 the firm earned “Buy” rating by H.C. Wainwright. On Tuesday, January 2 Stifel Nicolaus maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Thursday, March 29 Mizuho maintained the shares of AERI in report with “Buy” rating. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

AERI reached $68.5 during the last trading session after $0.45 change.Aerie Pharmaceuticals, Inc. has volume of 105,247 shares. Since June 27, 2017 AERI has declined 8.48% and is downtrending. AERI underperformed by 21.05% the S&P500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is worth $2.71 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

A couple more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were released by: Benzinga.com which released on June 22, 2018 “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap”, also Businesswire.com on June 18, 2018 released “Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel”, the next Gurufocus.com is “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares” on June 09, 2018. Businesswire.com has article titled “Aerie Pharmaceuticals to Present at the NASDAQ 38”.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.